UCB (OTCMKTS:UCBJF) Trading Down 11.9% – What’s Next?

Shares of UCB SA (OTCMKTS:UCBJF) traded down 11.9% during mid-day trading on Friday . The company traded as low as $260.3250 and last traded at $260.3250. 4 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 746 shares. The stock had previously closed at $295.59.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler reissued a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, UCB presently has a consensus rating of “Moderate Buy”.

UCB Price Performance

The stock’s 50 day simple moving average is $292.35 and its 200 day simple moving average is $300.27. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.